Neuronetics

Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003,[4] that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology. 

Neuronetics, Inc.
TypePublic
Nasdaq: STIM
Russell 2000 Index component
Founded2003
HeadquartersMalvern, PA, United States
Key people
Keith J. Sullivan
(President and CEO)[1][2]

Stephen Furlong (CFO)[1] Andrew Macan
(General counsel)[1]

[3]
Number of employees
167
As of March 31, 2018[4]
Websiteneurostar.com

Neuronetics became "first and only Food and Drug Administration (FDA) approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device (FDA approval K061053)."[5]

They manufacture a transcranial magnetic stimulation device, NeuroStar.[6] The NeuroStar TMS therapy is delivered via a precisely positioned magnetic coil against the patient's head.[7][8]

References
  1. "Neuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer" (Press release). Neuronetics. Retrieved July 15, 2020.
  2. "Neuronetics names new CEO". Seeking Alpha. Retrieved July 15, 2020.
  3. "NeuroStar Executive Team". Neuronetics.
  4. "Neuronetics, Inc. (stim) IPO". NASDAQ.com.
  5. Horvath, J. C.; Mathews, J.; Demitrack, M. A.; Pascual-Leone, A. (July 12, 2010). "The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression". Journal of Visualized Experiments (45): 2345. doi:10.3791/2345. PMC 3159591. PMID 21189465.
  6. "Hello Health: How transcranial magnetic stimulation treats major depressive disorder". November 11, 2020.
  7. "MercyOne TMS Therapy Des Moines, Iowa". YouTube. May 25, 2021.
  8. "Neuronetics' NeuroStar TMS device".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.